These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19695316)

  • 1. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
    Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
    Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
    Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
    Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
    Gocke E; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
    Gocke E; Bürgin H; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
    Müller L; Singer T
    Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
    Gocke E; Wall M
    Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General 4-week toxicity study with EMS in the rat.
    Pfister T; Eichinger-Chapelon A
    Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
    Gerber C; Toelle HG
    Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
    Gocke E; Ballantyne M; Whitwell J; Müller L
    Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
    Gocke E; Müller L
    Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Viracept-EMS case: impact and outlook.
    Walker VE; Casciano DA; Tweats DJ
    Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-linear dose-response of DNA-reactive genotoxins: recommendations for data analysis.
    Johnson GE; Doak SH; Griffiths SM; Quick EL; Skibinski DO; Zaïr ZM; Jenkins GJ
    Mutat Res; 2009 Aug; 678(2):95-100. PubMed ID: 19467345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
    Jia L; Coward LC; Kerstner-Wood CD; Cork RL; Gorman GS; Noker PE; Kitada S; Pellecchia M; Reed JC
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):63-73. PubMed ID: 17356822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
    Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
    Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.